dose-limiting acneiform rash. The company expects to report top-line results from this trial during the first half of 2025 at a major medical meeting. "Based on the broad use of EGFRi's to treat cancer and the dermal toxicity that often emerges,...
dose Phase 1 clinical trials studying STM-01 in patients with heart failure are expected to begin in the first quarter of 2025. STM-21: STM-21 is a secretome-based therapeutic comprised of the bioactive molecules secreted by nCPCs, such as...
myeloma in China. Ouro holds exclusive rights outside of Greater China and intends to start its first Phase 1 study in 2025. Examples of B cell mediated diseases include systemic lupus erythematosus, scleroderma, rheumatoid arthritis, Sjögren's,...
to evaluate safety, pharmacokinetics, and efficacy in patients. The trial is expected to initiate in the first half of 2025 and will be conducted by Mediar. Following completion of the Phase 2 study, Lilly will have the right to lead all further...
College of Pharmacy and Health Sciences with interactive health care events and programs beginning in the Fall semester of 2025 and encourage pharmacy students to pursue cosmetic science careers. Pharmacy students and members of the Cosmetic...
agreement dated December 4, 2024, with the approval of certain items in NLS's extraordinary general meeting on January 7, 2025. As previously detailed in NLS's Report on Form 6-K submitted to the Securities and Exchange Commission on December 4,...
to market faster. The company is also expanding its ISO 9001:2015 manufacturing capacity, which will be completed by mid-2025, to support more than $100 million in annual revenue and to demonstrate readiness to meet customers' demands as they scale...
Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). The stock options were approved on January 2, 2025 and were material to the employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock...
Executive Officer of ADC Therapeutics. "We look forward to completing enrollment of dose expansion in the first half of 2025 and plan to engage with regulatory authorities on the path forward as data including additional patients with longer...
Lodowski, Managing Director of Petauri Evidence, has been recognized as one of MM+M's esteemed 40 Under 40 honorees for 2025. Amanda Peterson, Vice President of Petauri Kinect, was also nominated. This annual award celebrates leaders from a range...
tumors with unmet medical needs. It is set to advance to its first U.S. IND submission and first patient dosing in 2025. As a monotherapy, PLT012 demonstrates remarkable anti-tumor efficacy in both immune 'hot' and 'cold' tumor models with a...
patients. An upcoming clinical trial for ST-001 targeting small cell lung cancer (SCLC) is anticipated to commence in Q2 2025. About ST-001: SciTech's lead drug candidate, ST-001 nanoFenretinide, is a patented nanoparticle formulation of...
in the lives of patients with ALS and are eager to move forward with our next clinical trial of NUZ-001 in early 2025." Impact on ALS Therapy and the Market: The ability of NUZ-001 to target TDP-43 aggregation and repair motor neuron function...
innovative drug therapies, today announced that it has received a PDUFA (Prescription Drug User Fee Act) date of June 2, 2025, for its LipidRescue Kit. If approved, the kit will treat LAST with the rapid and accurate infusion of a...
were transitioned to an expanded access protocol, and a report out of the PRECISION1 trial is expected to be provided in 2025. The Phase 2 trials of nab-sirolimus for advanced or recurrent endometrioid-type endometrial cancer (EEC) and...
generalized Myasthenia Gravis (gMG) and Thyroid Eye Disease (TED), with topline results expected in the first quarter of 2025 and first half of 2025, respectively. Additionally, HanAll, in collaboration with NurrOn Pharmaceuticals and Daewoong...
3 Study of Participants with Biochemical Recurrence of Prostate Cancer), is expected to begin patient recruitment in early 2025. The AMPLIFY trial will be a non-randomised, single-arm, open-label, multi-centre, Phase III diagnostic clinical trial...
and Fycompa in October 2024, and plans to expand activities to include Lenvima and anticancer agent Halaven from April 2025. Moreover, an application for Alzheimer’s disease treatment lecanemab has been submitted for review in Saudi Arabia. Saudi...
of Phase 2 in the next few months. We also expect to see the full Phase 1 results presented at a scientific meeting in 2025." "The available science increasingly highlights that fixed dosing at fixed intervals is unlikely to be optimal. Front...
as well as for our employees and business partners.” Financial details of the transaction were not disclosed. In FY2025, Bruker Biosensors expects additional revenues greater than $5 million from the DBS acquisition, with no material EPS impact....
